SIGNet’s functions are to:
- Link network Executive Officers
- Facilitate information sharing and mentoring of new Executive Officers
- Provide an opportunity to share insights on activities done well and to identify solutions to problems
- Provide updates from the sector and to receive updates from ACTA.
Mission:
SIGNet’s mission is to support and facilitate Clinical Trial Network (CTN) managers in optimal establishment and ongoing management of CTN operational activities to support the delivery of high-quality clinical research.
SIGNet provides a forum for Executive Officers, Network Managers and CTN representatives to share knowledge and expertise, identify issues, exchange information, and engage in collaborative problem solving.
ACTA seeks to engage CTNs in Australia through SIGNet meetings, ACTA events, and by sharing resources and providing advice and support to newly forming or formed CTNs. In the longer term, ACTA aims to improve the efficiency and effectiveness of clinical trial network management and governance.
Purpose:
SIGNet’s convenes 2-3 times a year with the purpose to:
- Link network Executive Officers
- Facilitate information sharing and mentoring of new Executive Officers
- Provide an opportunity to share insights on activities done well and to identify solutions to problems
- Provide updates from the sector and to receive updates from ACTA.
Actions:
Development of resources including a CTN Costing table and CTN activity reports. The activity reports are filled out by SIGNet Members and circulated before each meeting to share CTN updates and challenges, which can be discussed in meetings.
Presentations in meetings on topics including ‘which business legal structure to choose? Guidance for CTNs (2022) and Teletrials, by Prof Sabe Sabesan (2022).
ACTA have developed many resources for CTNs. Some developed during the 2021-2024 Grant period include:
- Business review of Clinical Trial Networks
- Activities supporting the growth of Clinical Trial Networks in Australia
- Fundraising strategy: guidance for CTNs
- Communications and marketing strategy: guidance for CTNs
Current CTNs that are represented in SIGNet
Australasian College for Emergency Medicine Clinical Trials Group (ACEM)
Australasian Gastro-Intestinal Trials Group (AGITG)
Australasian Kidney Trials Network (AKTN)
Australasian Leukemia and Lymphoma Group (ALLG)
Australasian Myeloma Research Consortium (AMaRC)
Australasian Nursing and Midwifery Clinical Trials Network (ANMCTN)
Australasian Radiopharmaceutical Trials Network (ARTnet)
Australasian Society for Infectious Diseases Clinical Research Network (ASID)
Australia & New Zealand Gynaecological Oncology Group (ANZGOG)
Australia and New Zealand Intesive Care Society (ANZICS)
Australia and New Zealand Musculoskeletal Clinical Trials Group (ANZMUSC)
Australia and New Zealand Sarcoma Association Limited (ANZSA)
Australian & New Zealand Urogenital & Prostate Cancer Trials Group (ANZUP)
Australian and New Zealand Alliance for Cardiovascular Trials (ANZACT)
Australian and New Zealand Children's Haematology/Oncology Group (ANZCHOG)
Australian and New Zealand College of Anaesthetists Clinical Trials Network (ANZCA)
Australian Early Psychosis Collaboration Consortium (AEPCC) CTN
Australian Genomic Cancer Medicine Centre (AGCM)
Breast Cancer Research Centre - Western Australia (BCRC-WA)
Breast Cancer Trials (BCT)
Centre for Eye Research Australia (CERA)
Child and Youth Mental Health CTN (CYMHS)
Clinical Trials Network Australia New Zealand (CTANZ)
Clinical Trials Network Australia New Zealand (CTANZ)
Cooperative Trials Group for Neuro-Oncology (COGNO)
Growing Minds Australia Clinical Trial Network (GMA-CTN)
Icon Institute of Innovation and Research
Juvenile Diabetes Research Foundation (JDRF)
Melanoma and Skin Cancer Trials (MASC Trials)
Melanoma and Skin Cancer Trials (MASC Trials)
Mental Health Australia General Clinical Trial Network (MAGNET)
Multiple Sclerosis Research Australia Clinical Trials Network (MSCTN)
National Endometriosis Clinical and Scientific Trials Network (NECST)
Neurodevelopment Australia
Neuroscience Trials Australia (NTA)
NSW Drug and Alcohol Clinical Research and Improvement Network (DACRIN)
Pulmonary Fibrosis Australasian Clinical Trials Network (PACT)
Palliative Care Clinical Studies Collaborative (PaCCSC)
Primary Care Collaborative Cancer Clinical Trials Group, University of Melbourne (PC4)
Psycho-oncology Co-operative Research Group (PoCoG)
Regional Trials Network - Victoria (RTN-Vic)
Thoracic Oncology Group of Australasia (TOGA)
University of Queensland Centre for Clinical Research (UQCCR)
Latest Resources
-
-
Approaches to prioritising research
for clinical trial networks: a scoping review -
HEAT Webinar Recording- Economic Evaluation Alongside Adaptive Trials
-
ACTA 2021-2022 Annual Report
-
Effective strategies to manage data integrity risks webinar
-
The Data Lifecycle: Ethical use of data webinar
-
Transparency in data analyses webinar
-
Economic evaluation alongside cluster trial – webinar recording
-
Development of the Consumer Involvement and Engagement Toolkit
-
Activities supporting the growth of Clinical Trial Networks in Australia
-
Strengthening the capacity, efficiency and effectiveness of Clinical Trials Networks: Activity Overview 2017–2021
-
ACTA 2020-2021 Annual Report
-
ACTA Whistleblower Policy
-
MEDIA RELEASE: ACTA appoints Prof Steve Webb as its new Chair and Ian Wilson as Additional Independent Director
-
Official Opening of the 2020 ACTA Summit: Minister’s Address
-
ACTA Year in Review: Financial Year 2019-2020
-
Statistical Analysis Plan (SAP)
-
ACTA Board Charter
-
ACTA Constitution
-
ACTA Trial of the Year Award 2020 guidelines and nomination forms
-
ACTA Year in Review: Financial Year 2018-2019
-
ACTA Resources Brochure
-
ACTA activity work plan 2019 – 2020
-
Report on the activities and achievements of clinical trials networks in Australia 2004 – 2014
-
What a trialist should know about implementation to practice
-
Submission to MRFF Consultation
-
Submission to Medical Research Future Fund Priority Consultation
-
Medical Research Future Fund – clinical trial funding set to deliver significant benefits to Australian patients and the economy
-
ACTA Advisory Council minutes July 2017
-
Economic evaluation of investigator-initiated clinical trials conducted by networks
-
Economic evaluation of investigator-initiated clinical trials conducted by networks – Appendix: Individual trial-level results
-
Open letter to the Hon Greg Hunt MP following announcement of MRFF funding for ACTA and clinical trials
-
How can clinical trials networks drive better translation of evidence into better quality care?
-
The Global Perspective: Measuring the impact of Australian-led trials & registries internationally
-
ACTA Summit 2016 – Opening address
-
ACTA Submission to the NHMRC Public Consultation on revisions to sections 3 & 5 of the National Statement
Latest News
-
ABSTRACTS NOW OPEN: ACTA 2023 International Clinical Trials Symposium
-
Celebrating REMAP – CAPs success on International Clinical Trials Day
-
Recommendations to improve cultural and linguistic diversity in clinical trials
-
ACTA National Tribute and Awards: 2023 TRIAL OF THE YEAR AWARD NOMINATIONS NOW OPEN
-
SAVE THE DATE: ACTA 2023 International Clinical Trials Symposium
-
ACTA Chair Steve Webb Podcast Interview
-
ACTA Teletrials Project – CTN and CC survey
-
Report update: Clinical trials landscape in Australia (2006 – 2020)
-
Celebrating a successful 2022 ACTA ASM including the Australian Registry ASM
-
ACTA’s response to the October 2022 budget announcements
-
Accolades for Australian clinical trials at annual ACTA awards
-
ACTA’s first Industry Roundtable
-
ACTA welcomes new CEO
-
A farewell message from our CEO
-
MRFF Australian Medical Research and Innovation Strategy and Priorities consultation and newly appointed Australian Medical Research Advisory Board
-
Australian Clinical Trials Alliance appoints Prof Steve Webb as its new Chair and Ian Wilson as Additional Independent Director
-
ACTA welcomes new $5 million grant from the MRFF
-
ACTA moving to virtual meetings in response to COVID-19
-
ACTA on Christmas break
-
ACTA—a year in review, 2018-2019 financial year
-
PREDICT (Paediatric Research in Emergency Departments International Collaborative) profile
-
Profiling Melanoma and Skin Cancer Trials
-
ACTA celebrates successful International Clinical Trials Conference
-
Workshop: Pragmatic randomised trial designs for evaluating health policy and practice change interventions
-
New ACTA Resources Brochure
-
Gala Dinner at Doltone House
-
International leaders in Clinical Trials meet in Sydney
-
Pre-Conference workshops
-
Gold Walkley recipient, Dr Norman Swan, confirmed as a speaker at ACTA Conference Gala Dinner
-
Conference speaker and Executive Director of CTTI releases recommendations for mobile technology trials
-
ACTA Annual General Meeting and Advisory Council Meeting
-
Health Economics 101 – designing cost-effectiveness studies alongside trials
-
Federal Minister for Health opening ACTA International Clinical Trials Conference
-
All.Can cancer survey highlights patient experience
-
ACTA Member finds prostate cancer pill gives patients 30% better survival rate
-
ACTA website survey
Latest Events
-
Sector consultations – online discussion with ACTA
-
Economic Evaluation Alongside Adaptive Trials webinar – 22 November
-
2022 ACTA ASM including the Australian Registry ASM
-
Improving clinical trial recruitment through innovative technologies
-
Clinical Quality Registries (CQR) SIG member webinar – Oct 2022
-
ACTA CEO update – October 2022
-
ACTA STInG 3 part webinar series on Data Transparency (DT)
-
ACTA CEO update – August 2022
-
Economic evaluation alongside cluster trial webinar
-
Clinical Trials (CT) Socials
-
Clinical Trials 2022: National Tribute and Awards
-
Clinical Trials 2021: National Tribute and Award Ceremony
-
Clinical Trials 2020: National Tribute and Award Ceremony
-
ACTA Summit and Clinical Trials 2020 National Tribute and Award Ceremony
-
ACTA Annual General Meeting
-
ACTA Advisory Council
-
ACTA International Clinical Trials Conference 2 – 5 October 2019